WestHill Financial Advisors’s CytomX Therapeutics CTMX Stock Holding History

WestHill Financial Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.1K	Hold	17,082	–	–	0.01%	82
2026 Q1	$80.3K	Hold	17,082	–	–	0.02%	76
2025 Q4	$72.8K	Hold	17,082	–	–	0.01%	81
2025 Q3	$54.5K	Hold	17,082	–	–	0.01%	78
2025 Q2	$38.8K	Hold	17,082	–	–	0.01%	72
2025 Q1	$10.9K	Hold	17,082	–	–	﹤0.01%	73
2024 Q4	$17.6K	Hold	17,082	–	–	﹤0.01%	78
2024 Q3	$20.2K	Hold	17,082	–	–	﹤0.01%	75
2024 Q2	$20.8K	Hold	17,082	–	–	0.01%	70
2024 Q1	$37.2K	Hold	17,082	–	–	0.01%	76
2023 Q4	$26.5K	Hold	17,082	–	–	0.01%	75
2023 Q3	$22K	Hold	17,082	–	–	0.01%	95
2023 Q2	$29.4K	Hold	17,082	–	–	0.01%	89
2023 Q1	$25.8K	Hold	17,082	–	–	0.01%	89
2022 Q4	$27.3K	Hold	17,082	–	–	0.01%	91
2022 Q3	$25K	Hold	17,082	–	–	0.01%	84
2022 Q2	$31K	Hold	17,082	–	–	0.01%	85
2022 Q1	$46K	Hold	17,082	–	–	0.01%	90
2021 Q4	$74K	Hold	17,082	–	–	0.02%	89
2021 Q3	$87K	Buy	+17,082	New	+$91.4K	0.03%	71
2021 Q1	$132K	Hold	17,082	–	–	0.05%	58
2020 Q4	$112K	Buy	+17,082	New	+$122K	0.04%	59

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

WestHill Financial Advisors's CTMX Position: Q2 2026 in Review

WestHill Financial Advisors held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 17,082 shares worth $64.1K. The position accounts for 0.01% of the portfolio, ranked #82.

WestHill Financial Advisors first reported a position in CTMX in Q4 2020 and has held it in 22 quarters since. The position peaked at $132K in Q1 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

WestHill Financial Advisors held 17,082 shares of CytomX Therapeutics worth $64.1K as of Q2 2026.
WestHill Financial Advisors left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up 0.01% of WestHill Financial Advisors's portfolio in Q2 2026, its #82 holding.
WestHill Financial Advisors first reported a position in CytomX Therapeutics in Q4 2020 and has held it in 22 quarters since.
WestHill Financial Advisors's CytomX Therapeutics position peaked at $132K in Q1 2021.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on WestHill Financial Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.